logo
ProjectCompleted

Weigao II

Sector: Residential • Location: China

Source: International Finance Corporation (IFC)

Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification

Status
Closed
Sector
Residential, Water Supply and Storage, Hospital, Steel, Government, Manufacturing (Industrial), Commercial, Metal
Location
China
Updated
22 Jul 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about Weigao II

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

4 Q
The project “Weigao II” is an infrastructure initiative in the Residential sector, located in China. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

completed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Weigao and its subsidiaries (together “the Group”) is the leading manufacturer of single-use medical devices in China. The Group has a wide range of products, which includes: (a) consumables (infusion set, syringes, medical needle, blood bags, pre-filled syringes, blood sampling products, and other consumables); (b) orthopedic materials (such as steel plates and screws); and (c) blood purification consumables (such as dialysis equipment). Weigao is listed on the Hong Kong Stock Exchange.The blood purification business is based in one of Weigao’s subsidiaries – Weigao Blood. Weigao Blood covers a wide range of blood purification medical devices including hemodialysis machines, high and low flux polysulfone membrane dialyzers and tubing system. In addition to manufacturing, Weigao blood also has a healthcare holding company known as Shandong Weigao Medical Holding Company Limited which runs hemodialysis centers. All the dialysis centers have facilities where patients receive treatment for about 4 hours twice or thrice a week. No patients stay overnight at these centers. The proposed IFC investment is a debt investment (A loan), proceeds of which will be used towards financing the expansion of Weigao’s blood purification business under its subsidiary, Weigao Blood, through: (i) the expansion of its manufacturing capacity for dialyzer, tubing and related consumables; and (ii) the opening additional company-operated standalone dialysis centers (together, the “Project”).  The expected size of the dialysis centers would be between 10 to 100 treatment beds.

Original sector

G-FA - Pharmaceuticals and Medicine Manufacturing

Location

Country

China

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Residential, Water Supply and Storage, Hospital, Steel, Government, Manufacturing (Industrial), Commercial, Metal

Article published date

2025-08-08

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project